IMMUTEP LTD ORDINARY (IMM) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXImmutep Presents Positive IMP761 Phase I Data at EULAR 2026
other announcement
Efti immune activation associated with improved survival
other announcement
Google NewsIs Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans? Yahoo Finance
Immutep Receives Nasdaq Notice of Bid Price Deficiency
other announcement
Immutep Quarterly Activities Report and Appendix 4C
other announcement
Abstract on Efti accepted for presentation at ASCO 2026
other announcement
Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint - Stocks Down Under
Immutep (ASX:IMM) wins FDA orphan status as efti Phase 2 hits 51.5% endpoint Stocks Down Under
Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
other announcement
Update on Phase I Study of IMP761 for Autoimmune Diseases
other announcement
_03_13_2026_05_52_01_191036.jpg)
KalkinePhase III Shock Sends Immutep Shares Into Steep Slide
Highlights Clinical study halt shakes confidence in biotech pipeline. Lung cancer program setback triggers sharp market reaction. Focus shifts toward remaining research programs. A halted late-stage lung cancer trial has placed the spotlight on the research pipeline of Immutep and renewed debate about the high-risk nature of biotech development. Inside Biotech: Phase III Setback Sends Immutep Shares Into Freefall Market attention quickly shifted to Immutep Ltd (ASX:IMM) following a majo...
TACTI-004 to be discontinued following futility analysis
other announcement
Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
other announcement
Immutep Quarterly Activities Report and Appendix 4C
other announcement
TACTI-004 phase III trial enrolment continues at robust pace
other announcement
Immutep enters into Strategic Collaboration with Dr. Reddy's
other announcement
Change of Director's Interest Notice - R Howard
director_dealing announcement
Change of Director's Interest Notice - P Meyers
director_dealing announcement
Change of Director's Interest Notice - L Boyce
director_dealing announcement
New data presentation from AIPAC-003 Phase II for SABCS
other announcement
EFTISARC-NEO Phase II results presented at CTOS 2025
other announcement
Immutep Receives A$4.6 million French R&D Tax Incentive
other announcement
Immutep Quarterly Activities Report and Appendix 4C
other announcement
Improved ORR in First Line NSCLC - presented at ESMO 2025
other announcement
Primary Endpoint Met in STS Trial - presented at ESMO 2025
other announcement